GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 • 5:00 EDT | Read More
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 4, 2023 • 9:05 EDT | Read More